These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 14517058)

  • 1. Human rhinovirus capsid dynamics is controlled by canyon flexibility.
    Reisdorph N; Thomas JJ; Katpally U; Chase E; Harris K; Siuzdak G; Smith TJ
    Virology; 2003 Sep; 314(1):34-44. PubMed ID: 14517058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pocket factors are unlikely to play a major role in the life cycle of human rhinovirus.
    Katpally U; Smith TJ
    J Virol; 2007 Jun; 81(12):6307-15. PubMed ID: 17428846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural studies on human rhinovirus 14 drug-resistant compensation mutants.
    Hadfield AT; Oliveira MA; Kim KH; Minor I; Kremer MJ; Heinz BA; Shepard D; Pevear DC; Rueckert RR; Rossmann MG
    J Mol Biol; 1995 Oct; 253(1):61-73. PubMed ID: 7473717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure of human rhinovirus complexed with Fab fragments from a neutralizing antibody.
    Smith TJ; Olson NH; Cheng RH; Liu H; Chase ES; Lee WM; Leippe DM; Mosser AG; Rueckert RR; Baker TS
    J Virol; 1993 Mar; 67(3):1148-58. PubMed ID: 7679742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. VP1 sequencing of all human rhinovirus serotypes: insights into genus phylogeny and susceptibility to antiviral capsid-binding compounds.
    Ledford RM; Patel NR; Demenczuk TM; Watanyar A; Herbertz T; Collett MS; Pevear DC
    J Virol; 2004 Apr; 78(7):3663-74. PubMed ID: 15016887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cryo-EM structure of pleconaril-resistant rhinovirus-B5 complexed to the antiviral OBR-5-340 reveals unexpected binding site.
    Wald J; Pasin M; Richter M; Walther C; Mathai N; Kirchmair J; Makarov VA; Goessweiner-Mohr N; Marlovits TC; Zanella I; Real-Hohn A; Verdaguer N; Blaas D; Schmidtke M
    Proc Natl Acad Sci U S A; 2019 Sep; 116(38):19109-19115. PubMed ID: 31462495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiviral agent blocks breathing of the common cold virus.
    Lewis JK; Bothner B; Smith TJ; Siuzdak G
    Proc Natl Acad Sci U S A; 1998 Jun; 95(12):6774-8. PubMed ID: 9618488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. VP4 protein from human rhinovirus 14 is released by pressure and locked in the capsid by the antiviral compound WIN.
    Gonçalves RB; Mendes YS; Soares MR; Katpally U; Smith TJ; Silva JL; Oliveira AC
    J Mol Biol; 2007 Feb; 366(1):295-306. PubMed ID: 17161425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural and virological studies of the stages of virus replication that are affected by antirhinovirus compounds.
    Zhang Y; Simpson AA; Ledford RM; Bator CM; Chakravarty S; Skochko GA; Demenczuk TM; Watanyar A; Pevear DC; Rossmann MG
    J Virol; 2004 Oct; 78(20):11061-9. PubMed ID: 15452226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human rhinovirus type 16: mutant V1210A requires capsid-binding drug for assembly of pentamers to form virions during morphogenesis.
    Lee WM; Wang W
    J Virol; 2003 Jun; 77(11):6235-44. PubMed ID: 12743280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody-mediated neutralization of human rhinovirus 14 explored by means of cryoelectron microscopy and X-ray crystallography of virus-Fab complexes.
    Che Z; Olson NH; Leippe D; Lee WM; Mosser AG; Rueckert RR; Baker TS; Smith TJ
    J Virol; 1998 Jun; 72(6):4610-22. PubMed ID: 9573224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Docking of a human rhinovirus neutralizing antibody onto the viral capsid.
    Tormo J; Centeno NB; Fontana E; Bubendorfer T; Fita I; Blaas D
    Proteins; 1995 Dec; 23(4):491-501. PubMed ID: 8749845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel basis of capsid stabilization by antiviral compounds.
    Phelps DK; Post CB
    J Mol Biol; 1995 Dec; 254(4):544-51. PubMed ID: 7500332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Binding affinities of structurally related human rhinovirus capsid-binding compounds are related to their activities against human rhinovirus type 14.
    Fox MP; McKinlay MA; Diana GD; Dutko FJ
    Antimicrob Agents Chemother; 1991 Jun; 35(6):1040-7. PubMed ID: 1656851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutralizing antibody to human rhinovirus 14 penetrates the receptor-binding canyon.
    Smith TJ; Chase ES; Schmidt TJ; Olson NH; Baker TS
    Nature; 1996 Sep; 383(6598):350-4. PubMed ID: 8848050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonneutralizing human rhinovirus serotype 2-specific monoclonal antibody 2G2 attaches to the region that undergoes the most dramatic changes upon release of the viral RNA.
    Hewat EA; Blaas D
    J Virol; 2006 Dec; 80(24):12398-401. PubMed ID: 17005641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dissociation of an antiviral compound from the internal pocket of human rhinovirus 14 capsid.
    Li Y; Zhou Z; Post CB
    Proc Natl Acad Sci U S A; 2005 May; 102(21):7529-34. PubMed ID: 15899980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. WIN 52035-2 inhibits both attachment and eclipse of human rhinovirus 14.
    Shepard DA; Heinz BA; Rueckert RR
    J Virol; 1993 Apr; 67(4):2245-54. PubMed ID: 8383239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular dynamics simulations of human rhinovirus and an antiviral compound.
    Speelman B; Brooks BR; Post CB
    Biophys J; 2001 Jan; 80(1):121-9. PubMed ID: 11159387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A model for compounds active against human rhinovirus-14 based on X-ray crystallography data.
    Diana GD; Treasurywala AM; Bailey TR; Oglesby RC; Pevear DC; Dutko FJ
    J Med Chem; 1990 May; 33(5):1306-11. PubMed ID: 2158559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.